Akorn vs Moderna, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $682 M for Akorn in the year to December 2019.
- Both made a net loss: $227 M for Akorn and $2.8 B for Moderna, Inc.
- Akorn keeps more of each dollar of sales: a net margin of -33.2% against -145.2% for Moderna, Inc.
Market cap history
● Akorn● Moderna, Inc.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Akorn AKRXQ | Moderna, Inc. MRNA · #275 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | — | 2010 |
| Size | ||
| Market cap | — | $90.1 B |
| Revenue | $682 M | $1.9 B |
| Net income | $-227 M▲ best | $-2.8 B |
| Employees | — | 4,700 |
| Valuation | ||
| Price to sales | — | 35.7× |
| Price to book | — | 10.4× |
| Free cash flow yield | — | -2.3% |
| Profitability | ||
| Gross margin | — | 55.4% |
| Operating margin | — | -158.1% |
| Net margin | — | -145.2% |
| Return on equity | — | -28.9% |
| Growth | ||
| Revenue growth | — | -39.9% |
| Revenue growth, 3 years a year | — | -53.4% |
| Financial strength | ||
| Debt to equity | — | 0.1× |
| Cash | ||
| Free cash flow margin | — | -106.2% |
| Shareholder returns | ||
| Shareholder yield | — | 0.0% |
| Strength scores | ||
| Piotroski F-score | — | 3 of 9 |
| Altman Z-score zone | — | safe |
| Data as of | Market cap — | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which makes more money, Akorn or Moderna, Inc.?
Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $682 M for Akorn in the year to December 2019. Both made a net loss: $227 M for Akorn and $2.8 B for Moderna, Inc.
Which is more profitable, Akorn or Moderna, Inc.?
Akorn keeps more of each dollar of sales: a net margin of -33.2% against -145.2% for Moderna, Inc.
More about Akorn
More about Moderna, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.